Latest news

• AbbVie’s blockbuster-in-waiting for endometriosis gets FDA nod

  uterine fibroids are approved by regulators. ... Their relugolix candidate has positive mid-stage results in endometriosis-related pain, uterine fibroids, and prostate cancer, and is currently in phase III testing with some results due next year.

• AbbVie’s uterine fibroids drug aces second phase III trial

  or in early 2019, setting up a possible launch in uterine fibroids in 2020. ... Elagolix isn’t the only drug aiming to provide an oral therapy for uterine fibroids.

• MHRA suspends new prescriptions of fibroid drug Esmya

  In December, the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) started a review of the treatment for abnormal bleeding in women with uterine fibroids after four cases of serious liver injury - ... Esmya (ulipristal acetate) is a selective

• Joerg Moeller to head Bayer R&D after operational shake-up

  testing, vericiguat and neladenoson bialanate for heart failure, and progress in gynaecology with six candidates in clinical development for uterine fibroids and endometriosis.

• Bayer moves vilaprisan into phase III trials for uterine fibroids

  Bayer moves vilaprisan into phase III trials for uterine fibroids. ASTEROID study will investigate safety and efficacy of the novel drug. ... Uterine fibroids are the most common benign gynecological tumors, with approximately 5-10% of women requiring